PB
Pedro C Barata
University Hospitals Seidman Cancer Center, Tulane University School of Medicine, Taussig Cancer Institute, Unidade Local de Saúde de São José, Cleveland Clinic Foundation, Universidade Nova de Lisboa
Research areas: Medicine · Oncology · Prostate Cancer Treatment and Research · Prostate Cancer Diagnosis and Treatment · Cancer Immunotherapy and Biomarkers
0000-0002-8890-2951
Employment
-
University Hospitals Seidman Cancer Center Associate Professor of Medicine2022 - Present
-
Tulane University School of Medicine Assistant Professor2018 - 2022
-
Cleveland Clinic Foundation Experimental Therapeutics Fellow2016 - 2018
- 2011 - 2016
Education
-
Taussig Cancer Institute Clinical Fellowship in Genitourinary Cancers2016 - 2018
-
Centro Hospitalar de Lisboa Central Fellowship2011 - 2016
- 2003 - 2009
-
Universidade de Lisboa Faculdade de Medicina MSc Palliative Care? - 2016
Projects & Funding
Projects & funding information is unavailable.
Publications (264)
- Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer Save
- Risk-informed Stratification and Counseling for Adjuvant Pembrolizumab in Clear Cell Renal Cell Carcinoma Save
- From Guidelines to Practice: Mainstreaming Germline Testing in Prostate Cancer Save
- Modernizing disease assessment in prostate cancer trials: the Prostate Cancer Working Group 4 framework Save
- Management of Renal Cell Carcinoma of Variant Histology Save
- Data from Molecular Characterization of KLK2 RNA Expression in Prostate Cancer Save
- Molecular Characterization of KLK2 RNA Expression in Prostate Cancer Save
- Supplementary Data1 from Molecular Characterization of KLK2 RNA Expression in Prostate Cancer Save
- Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer Save
- Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025 Save
- Re: Final Overall Survival and Safety Analyses of the Phase III PSMAfore Trial of [177Lu]Lu-PSMA-617 Versus Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Save
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0 Save
- Balancing Cure and Quality of Life: Navigating Functional Outcomes in Localized Prostate Cancer Save
- Radiographic progression-free survival as a surrogate endpoint for overall survival in first-line ARPi naïve metastatic castration-resistant prostate cancer Save
- Consensus and controversy in advanced urologic cancers: Insights from the Advanced Urologic Cancer Consensus Conference (AUC3) 2025 Save
- EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer Save
- Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer Save
- Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 Save
- Addressing quality-of-life challenges for patients with end-stage metastatic castrate-resistant prostate cancer Save
- Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer Save